BrightSpring Health Services, Inc.

BTSG

Nasdaq; healthcare; SIC 8082, Services-Home Health Care Services; CIK 0001865782

B

second fifth of 305 graded peers in healthcare

rank 112 of 305; percentile 36.5; sampling error 2.8 points; lower is stronger

A B C D E

B, the elk



Scoreboard	
Profitability	C/D percentile 60.8
Solvency	C percentile 56.2
Growth and financing	A percentile 10.0
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $6.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	8 of 13
Graded from	filings received through Feb 27, 2026 265 days before the rescan; latest periodic filing 10-Q received Oct 30, 2026
Last close	$68.33 2026-11-18; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

We are a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. We have a differentiated approach to care delivery, with an integrated and scaled model that addresses critical services that the highest-need and highest-cost patients require. With a focus on Senior and Specialty patients, which includes Behavioral populations, our platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to Medicare, Medicaid, and commercially-insured populations.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 60.8						
Gross profitability	23.7%	32.8%		58.3	346	2025-12-31
Return on invested capital	5.3%	9.6%		62.3	70	2025-12-31
Accruals ratio	(4.9%)	(6.7%)		61.9	756	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 2						
Solvency, sleeve percentile 56.2						
Altman Z double-prime	1.78	0.31		30.4	705	2025-12-31
Net debt to EBITDA	6.59x	1.82x		91.7	73	2025-12-31
Interest coverage	1.88x	(3.61x)		21.9	74	2025-12-31
Current ratio	1.57x	2.68x		80.8	781	2025-12-31
Growth and financing, sleeve percentile 10.0						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	269.3%	33.9%		10.0	101	2025-12-31
Asset growth, three years	not computable	3.2%				
four annual observations are required; found 2						
Net share issuance, one year	not computable	1.6%				
firm-wide XBRL shares cannot be assigned to one ticker class						

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
107	Tandem Diabetes Care Inc. (TNDM)	34.9	B	
108	CVRx, Inc. (CVRX)	35.2	B	
109	InfuSystem Holdings, Inc. (INFU)	35.5	B	
110	Eton Pharmaceuticals, Inc. (ETON)	35.9	B	
111	Koru Medical Systems, Inc. (KRMD)	36.2	B	fortress balance sheet
112	BrightSpring Health Services, Inc. (BTSG)	36.5	B	
113	Ionis Pharmaceuticals Inc. (IONS)	36.8	B	
114	ImmunityBio, Inc. (IBRX)	37.2	B	short runway
115	Apyx Medical Corp. (APYX)	37.5	B/C	
116	Glaukos Corp. (GKOS)	37.8	B/C	fortress balance sheet
117	Insmed Inc. (INSM)	38.2	B/C	

What the price implies

at the 2026-11-18 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	71.7%	(1.7%)	86
Distance from 52-week high	(6.3%)	(30.2%)	80
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	not computable	0.29	
Sales to price	not computable	0.36	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	0.37	(0.19)	86
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$717.8M
Operating cash flow, four quarters	$602.7M
Months of runway	not finite
Days since last periodic filing	20 (10-Q received Oct 30, 2026)
Median daily dollar volume, 63 sessions	$129.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.5B	2025-12-31	2026-02-27	10-K	26-079454
2	assets	us-gaap:Assets	$6.4B	2025-12-31	2026-02-27	10-K	26-079454
3	operating income	us-gaap:OperatingIncomeLoss	$295.3M	2025-12-31	2026-02-27	10-K	26-079454
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$137.9M	2025-12-31	2026-02-27	10-K	26-079454
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$33.1M	2025-12-31	2026-02-27	10-K	26-079454
6	total debt	us-gaap:LongTermDebt	$2.5B	2025-12-31	2026-02-27	10-K	26-079454
7	book equity	us-gaap:StockholdersEquity	$1.9B	2025-12-31	2026-02-27	10-K	26-079454
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$88.4M	2025-12-31	2026-02-27	10-K	26-079454
9	total debt	us-gaap:LongTermDebt	$2.6B	2024-12-31	2026-02-27	10-K	26-079454
10	book equity	us-gaap:StockholdersEquity	$1.6B	2024-12-31	2026-02-27	10-K	26-079454
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$61.0M	2024-12-31	2026-02-27	10-K	26-079454
12	net income	us-gaap:NetIncomeLoss	$190.7M	2025-12-31	2026-02-27	10-K	26-079454
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$490.2M	2025-12-31	2026-02-27	10-K	26-079454
14	assets	us-gaap:Assets	$5.9B	2024-12-31	2026-02-27	10-K	26-079454
15	current assets	us-gaap:AssetsCurrent	$2.9B	2025-12-31	2026-02-27	10-K	26-079454
16	current liabilities	us-gaap:LiabilitiesCurrent	$1.8B	2025-12-31	2026-02-27	10-K	26-079454
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$74.6M	2025-12-31	2026-02-27	10-K	26-079454
18	liabilities	us-gaap:Liabilities	$4.5B	2025-12-31	2026-02-27	10-K	26-079454
19	depreciation amortization	us-gaap:Depreciation	$71.8M	2025-12-31	2026-02-27	10-K	26-079454
20	interest expense	us-gaap:InterestExpense	$157.3M	2025-12-31	2026-02-27	10-K	26-079454
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$12.9B	2025-12-31	2026-02-27	10-K	26-079454
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.1B	2024-12-31	2026-02-27	10-K	26-079454
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$95.5M	2025-12-31	2026-02-27	10-K	26-079454
24	current assets	us-gaap:AssetsCurrent	$1.9B	2024-12-31	2026-02-27	10-K	26-079454
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.4B	2024-12-31	2026-02-27	10-K	26-079454

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.